^
Association details:
Biomarker:MSI-H/dMMR
Cancer:Germ Cell Tumors
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Second-line and Subsequent Therapy for Metastatic Germ Cell Tumors...Additionally, the panel considers pembrolizumab immunotherapy to be useful In certain circumstances (ie, in patients with MSI-high/deficient MMR [MSI-H/dMMR] tumors.
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Small Intestinal Carcinoma)
New
Title:

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

Excerpt:
Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.